Legal Advantage Investments Inc. Acquires 10,000 Shares of GeneDx Holdings Corp. $WGS

Legal Advantage Investments Inc. lifted its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 19.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 60,600 shares of the company’s stock after buying an additional 10,000 shares during the quarter. GeneDx makes up 2.6% of Legal Advantage Investments Inc.’s holdings, making the stock its 12th largest holding. Legal Advantage Investments Inc.’s holdings in GeneDx were worth $5,594,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of WGS. GAMMA Investing LLC raised its position in shares of GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after purchasing an additional 264 shares during the last quarter. US Bancorp DE raised its position in shares of GeneDx by 3,223.5% in the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after purchasing an additional 548 shares during the last quarter. KBC Group NV purchased a new position in shares of GeneDx in the 1st quarter worth about $81,000. PNC Financial Services Group Inc. purchased a new position in shares of GeneDx in the 1st quarter worth about $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of GeneDx by 184.8% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,224 shares of the company’s stock worth $197,000 after purchasing an additional 1,443 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research report on Wednesday. Guggenheim reaffirmed a “buy” rating and issued a $115.00 price target (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wells Fargo & Company boosted their target price on GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th. Wall Street Zen raised GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Piper Sandler boosted their target price on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and an average target price of $104.13.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the sale, the chief executive officer directly owned 14,578 shares in the company, valued at $1,770,789.66. The trade was a 41.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director owned 103,284 shares of the company’s stock, valued at approximately $13,148,053.20. This represents a 26.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 556,371 shares of company stock valued at $67,489,314. 29.60% of the stock is owned by company insiders.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $121.72 on Friday. The business has a 50-day simple moving average of $121.39 and a two-hundred day simple moving average of $95.22. The firm has a market cap of $3.50 billion, a price-to-earnings ratio of 2,434.40 and a beta of 1.98. GeneDx Holdings Corp. has a fifty-two week low of $54.14 and a fifty-two week high of $136.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million during the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. On average, analysts expect that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.